StockNews.AISignal intelligence
Becton, Dickinson and Company · NYSE · Healthcare
Browse public BDX signals with their source context and measured market impact. Open any signal for its permanent analysis page.
BD said it is recalling certain U.S. needle sets after users reported difficulty removing a component post-use. The company provided no cost estimates or scope details. The recall introduces near-term cost and regulatory scrutiny risk and could pressure margins or sentiment in the device segment until the issue is clarified.
View signal analysisBecton Dickinson has raised its annual profit forecast, fueled by robust demand for its drug-delivery devices and surgical equipment. The appointment of Vitor Roque as CFO further solidifies the company's strategy toward growth, which may positively influence investor sentiment and stock performance.
View signal analysisBecton Dickinson (BDX) reported revenue of $5.25 billion, exceeding the consensus estimate of $5.15 billion. This strong performance may boost investor sentiment and provide momentum for BDX's share price in the short term.
View signal analysisBecton Dickinson (BDX) has lowered its profit forecast for fiscal year 2026 due to the impending separation and sale of its biosciences and diagnostics unit to Waters Corporation. This shift may impact BDX's revenue stream and investor confidence, leading to increased scrutiny on future financial performance.
View signal analysisBecton Dickinson (BDX) is set to release its Q1 earnings on February 9, which could significantly impact the stock's short-term volatility based on performance indicators. Investors should closely monitor results for insights on revenue growth and margin performance, which are critical in the current economic environment.
View signal analysisFDA grants clearance for BDX's new breast biopsy system. The system improves biopsy procedures across multiple imaging modalities. Market cap is $59.10 billion with a 52-week range of $162.29-$251.99. Analysts project EPS of $2.82, down from $3.43 last year. Consensus rating is 'Buy' with a target price of $245.93.
View signal analysis